This website does not list all Teva-sponsored clinical trials. If you have a question about Teva clinical trials, please email USMedInfo@tevapharm.com or call 1-888-483-8279.
Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
Condition(s):
Pain
Status:
Completed
Requirements:
18 Years to 45 Years
Interventions:
Drug: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
Condition(s):
Pain
Status:
Completed
Requirements:
18 Years to 45 Years
Interventions:
Drug: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.